Upside Biotechnologies, a regenerative medicine start-up, said it has successfully raised $2.3 million in its Series A funding round.
The Auckland-based company is developing an advanced, world-class skin replacement treatment for patients suffering major burns. The capital raised will be used to complete development of the product, demonstrate proof of concept, ready the product for its first human trial and forge links and explore market opportunities in the US, chief executive Robert Feldman said in a statement.

Read more

Please follow and like us: